Arbutus Biopharma Corp: Form 10-K for the period ended Dec 31, 2016
Filed with the SEC on Mar 22, 2017 and accepted by EDGAR at Mar 22, 2017, 06:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-10-01 to 2016-12-31 | −$195.0k | us-gaap:Revenues |
| Revenue | 12 months2016-01-01 to 2016-12-31 | $1.5m | us-gaap:Revenues |
| Research and development | 12 months2016-01-01 to 2016-12-31 | $61.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-10-01 to 2016-12-31 | −$257.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2016-01-01 to 2016-12-31 | −$491.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2016-01-01 to 2016-12-31 | −$105.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-10-01 to 2016-12-31 | −$218.7m | us-gaap:NetIncomeLoss |
| Net income | 12 months2016-01-01 to 2016-12-31 | −$384.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-10-01 to 2016-12-31 | −$4.05 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 12 months2016-01-01 to 2016-12-31 | −$7.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2016-01-01 to 2016-12-31 | −$7.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2016-01-01 to 2016-12-31 | 53,074,401 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2016-01-01 to 2016-12-31 | −$57.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2016-01-01 to 2016-12-31 | $4.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-12-31 | $23.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-12-31 | $132.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-12-31 | $275.9m | us-gaap:Assets |
| Current liabilities | At period end2016-12-31 | $10.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-12-31 | $72.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-12-31 | $203.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-17-002760. Last ingested by Listed: Nov 12, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.